Recently, JPMorgan Chase held the first Global Healthcare Industry Annual Conference Shanghai Forum in Shanghai. The forum, which was strongly supported by the Shanghai Municipal Government, brought together representatives of pharmaceutical giants and experts and financial institutions at home and abroad to discuss many important topics such as the rise of China's biotechnology field, vaccine development and artificial intelligence applications, and explore the important role of the capital market in supporting the development of the medical and health industry. Du Meng, Deputy General Manager and Investment Director of Shanghai Investment Morgan Fund, was invited to attend the forum and participate in the roundtable forum with the theme of "Investment Strategy and Prospects of Healthcare Industry".
Du Meng said that in recent years, the national policy environment for supporting innovation, the engineer dividend, and the huge support of the capital market, the above three aspects have resonated at the current point in time, making the current investment environment of China's medical health usher in a rare historic opportunity. Under the background of the division of labor in the global pharmaceutical innovation industry chain, Chinese companies can use sufficient human capital and capital investment to gain competitive advantages, and are expected to make eye-catching achievements in R&D outsourcing and innovative drugs going overseas.
Du Meng further pointed out that in the domestic health care market, the medium- and long-term opportunities in the consumer and service tracks are also worth promising. Whether it is the acceleration of China's aging or the growth in demand for health with the increase in per capita GDP and income, it means that related fields will maintain high growth in the medium and long term.
"Pharmaceutical investment is highly professional, and it is better to participate in it through excellent fund management companies or better choices." Du Meng said that the investment research of pharmaceutical companies does have a certain degree of professionalism, especially for companies with high technical barriers, understanding the advantages of research and development technology itself and the competitive landscape of the entire technical field are all compulsory courses for research. In this regard, Shanghai Investment Morgan Fund has established a professional investment research team, from the perspective of internationalization and full cycle, covering A-shares, Hong Kong stocks and US stocks; the product line covers A-shares and QDII funds.
When it comes to pharmaceutical investment research, Du Meng stressed that the research of the pharmaceutical industry needs an overall perspective and ideas, and also needs to focus on profound research. Therefore, the investment research of Shanghai Investment Morgan Fund in this field is not limited to a single listed company, but also actively pays attention to some early and medium-term technology trends and companies in the industrial chain. Since the pharmaceutical industry is an ever-changing and highly growing industry, it is necessary to keep up with the most cutting-edge developments in a timely manner and grasp the development status of multiple sub-fields, so as to establish a complete knowledge base within the company. Therefore, before the wave of a certain industry rises, the Shanghai Investment Morgan Fund has already done in-depth research on the industry, and it is more handy when the opportunity comes.
![The big guy's "trend exposure" in the third quarter: Fu Pengbo's "circle of friends" took root in Real Madrid technology, and Du Meng cashed in Tianhua's ultra-clean[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)